Drug-induced cholestasis

Hepatology

Volumn 53, Issue 4, 2011, Pages 1377-1387

  Padda, Manmeet S ^a   Sanchez, Mayra ^b   Akhtar, Abbasi J ^c   Boyer, James L ^b  

^a Division of Gastroenterology   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMOXICILLIN PLUS CLAVULANIC ACID; ATORVASTATIN; AZATHIOPRINE; CAPTOPRIL; CARBAMAZEPINE; CARRIER PROTEIN; CELECOXIB; CYCLOSPORIN A; FLOXURIDINE; GLIBENCLAMIDE; HALOPERIDOL; HALOTHANE; ISONIAZID; METFORMIN; METHYLDOPA; METOLAZONE; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PROPAFENONE; REPAGLINIDE; RIFAMPICIN; TAMOXIFEN; TENOXICAM; TRICYCLIC ANTIDEPRESSANT AGENT; TROGLITAZONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VERAPAMIL;

ABDOMINAL PAIN; BILE DUCT DISEASE; BILE DUCT INJURY; BILIARY CIRRHOSIS; CHOLESTASIS; CLINICAL FEATURE; DETOXIFICATION; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG INDUCED CHOLESTASIS; GENETIC VARIABILITY; HEPATITIS; HUMAN; INTERSTITIAL NEPHRITIS; LACRIMAL GLAND DISEASE; LIVER CELL; LIVER HISTOLOGY; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PRURITUS; REVIEW; SCLEROSING CHOLANGITIS; VANISHING BILE DUCT SYNDROME; XANTHOMA;

CARRIER PROTEINS; CHOLESTASIS; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER DISEASES; PHARMACEUTICAL PREPARATIONS;

EID: 79953763068     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24229     Document Type: Review

References (83)

1. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-485.
2. Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010; 33: 503-522.
3. Assis DN, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opin Drug Metab Toxicol 2009; 5: 463-473.
4. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al.; US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. HEPATOLOGY 2010; 51: 2117-2126.
5. Bohan A, Boyer JL. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin Liver Dis 2002; 22: 123-136.
6. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. HEPATOLOGY 2005; 42: 481-489.
7. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. HEPATOLOGY 2010; 51: 615-620.
8. Geubel AP, Sempoux CL. Drug and toxin-induced bile duct disorders. J Gastroenterol Hepatol 2000; 15: 1232-1238.
9. Popper H, Schaffner F. Pathophysiology of cholestasis. Hum Pathol 1970; 1: 1-24.
10. Zimmerman HJ. Intrahepatic cholestasis. Arch Intern Med 1979; 139: 1038-1045.
11. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992; 232: 133-138.
12. Lewis JH. Drug-induced liver disease. Med Clin North Am 2000; 84: 1275-1311.
13. Bjørneboe M, Iversen O, Olsen S. Infective hepatitis and toxic jaundice in a municipal hospital during a five-year period: incidence and prognosis. Acta Med Scand 1967; 182: 491-501.
14. Malchow-Møller A, Matzen P, Bjerregaard B, Hilden J, Holst-Christensen J, Staehr Johansen T, et al. Causes and characteristics of 500 consecutive causes of jaundice. Scand J Gastroenterol 1981; 16: 1-6.
15. Whitehead MW, Hainsworth I, Kingham JG. The causes of obvious jaundice in South West Wales: perceptions versus reality. Gut 2001; 48: 409-413.
16. Bjornsson E, Ismael S, Nejdet S, Kilander A. Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. Scand J Gastroenterol 2003; 38: 86-94.
17. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002; 22: 169-183.
18. Viteri AL, Greene JF Jr, Dyck WP. Erythromycin ethylsuccinate-induced cholestasis. Gastroenterology 1979; 76: 1007-1008.
19. Walker CO, Combes B. Biliary cirrhosis induced by chlorpromazine. Gastroenterology 1966; 51: 631-640.
20. Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, et al. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. HEPATOLOGY 1994; 20: 1437-1441.
21. Erlinger S. Drug-induced cholestasis. J Hepatol 1997; 26( Suppl 1): 1-4.
22. Hautekeete ML, Brenard R, Horsmans Y, Henrion J, Verbist L, Derue G, et al. Liver injury related to amoxycillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations. J Hepatol 1995; 22: 71-77.
23. Alonso-Ruiz A, Calabozo M, Perez-Ruiz F, Mancebo L. Toxic oil syndrome. A long-term follow-up of a cohort of 332 patients. Medicine (Baltimore) 1993; 72: 285-295.
24. Degott C, Feldmann G, Larrey D, Durand-Schneider AM, Grange D, Machayekhi JP, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. HEPATOLOGY 1992; 15: 244-251.
25. Moreno A, Carreño V, Cano A, González C. Idiopathic biliary ductopenia in adults without symptoms of liver disease. N Engl J Med 1997; 336: 835-838.
26. Geubel AP, Sempoux C, Rahier J. Bile duct disorders. Clin Liver Dis 2003; 7: 295-309.
27. Desmet VJ. Destructive intrahepatic bile duct diseases. Recent Prog Med 1990; 81: 392-398.
28. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339: 1217-1227.
29. Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and drug-induced cholestasis. HEPATOLOGY 2006; 44: 778-787.
30. DeLeve LD, Kaplowitz N. Mechanisms of drug-induced liver disease. Gastroenterol Clin North Am 1995; 24: 787-810.
31. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6: 755-774.
32. Stieger B. Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug Metab Rev 2010; 42: 437-445.
33. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Steiger B, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001; 69: 223-231.
34. Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, et al. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 2001; 167: 83-98.
35. Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001; 59: 627-635.
36. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000; 118: 422-430.
37. Bolder U, Trang NV, Hagey LR, Schteingart CD, Ton-Nu HT, Cerrè C, et al. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology 1999; 117: 962-971.
38. Bohme M, Buchler M, Muller M, Keppler D. Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 1993; 333: 193-196.
39. Kadmon M, Klünemann C, Böhme M, Ishikawa T, Gorgas K, Otto G, et al. Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. Gastroenterology 1993; 104: 1507-1514.
40. Böhme M, Müller M, Leier I, Jedlitschky G, Keppler D. Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. Gastroenterology 1994; 107: 255-265.
41. Roman ID, Monte MJ, Gonzalez-Buitrago JM, Esteller A, Jimenez R. Inhibition of hepatocytary vesicular transport by cyclosporin A in the rat: relationship with cholestasis and hyperbilirubinemia. HEPATOLOGY 1990; 12: 83-91.
42. Roman ID, Coleman R. Disruption of canalicular function in isolated rat hepatocyte couplets caused by cyclosporin A. Biochem Pharmacol 1994; 48: 2181-2188.
43. Roman ID, Fernandez-Moreno MD, Fueyo JA, Roma MG, Coleman R. Cyclosporin A induced internalization of the bile salt export pump in isolated rat hepatocyte couplets. Toxicol Sci 2003; 71: 276-281.
44. Yasumiba S, Tazuma S, Ochi H, Chayama K, Kajiyama G. Cyclosporin A reduces canalicular membrane fluidity and regulates transporter function in rats. Biochem J 2001; 354: 591-596.
45. Bramow S, Ott P, Thomsen Nielsen F, Bangert K, Tygstrup N, Dalhoff K. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin). Pharmacol Toxicol 2001; 89: 133-139.
46. Kostrubsky VE, Vore M, Kindt E, Burliegh J, Rogers K, Peter G, et al. The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats. Drug Metab Dispos 2001; 29: 1561-1566.
47. Kleiner DE, Gaffey MJ, Sallie R, Tsokos M, Nichols L, McKenzie R, et al. Histopathologic changes associated with fialuridine hepatotoxicity. Mod Pathol 1997; 10: 192-199.
48. Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994; 145: 1237-1245.
49. Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007; 17: 47-60.
50. Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF, et al. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab Dispos 2006; 34: 1575-1581.
51. Kassianides C, Nussenblatt R, Palestine AG, Mellow SD, Hoofnagle JH. Liver injury from cyclosporine A. Dig Dis Sci 1990; 35: 693-697.
52. Dietrich CG, Ottenhoff R, de Waart DR, Oude Elferink RP. Role of MRP2 and GSH in intrahepatic cycling of toxins. Toxicology 2001; 167: 73-81.
53. Davies MH, Harrison RF, Elias E, Hübscher SG. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol 1994; 20: 112-116.
54. Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis 2008; 12: 203-217.
55. Bataille L, Rahier J, Geubel A. Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease. J Hepatol 2002; 37: 696-699.
56. Okan G, Yaylaci S, Peker O, Kaymakoglu S, Saruc M. Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus. World J Gastroenterol 2008; 14: 4697-4700.
57. Velayudham LS, Farrell GC. Drug-induced cholestasis. Expert Opin Drug Saf 2003; 2: 287-304.
58. Choi SH, Yang SH, Song YB, Kim HJ, Seo YT, Choi DS, et al. A case of vanishing bile duct syndrome associated with hypersensitivity to allopurinol. [in Korean] Korean J Hepatol 2005; 11: 80-85.
59. Capra F, Nicolini N, Morana G, Guglielmi A, Capelli P, Vantini I. Vanishing bile duct syndrome and inflammatory pseudotumor associated with a case of anabolic steroid abuse. Dig Dis Sci 2005; 50: 1535-1537.
60. Srivastava M, Perez-Atayde A, Jonas M. Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child. Gastroenterology 1998; 115: 743-746.
61. Taghian M, Tran TA, Bresson-Hadni S, Menget A, Felix S, Jacquemin E. Acute vanishing bile duct syndrome after ibuprofen therapy in a child. J Pediatr 2004; 145: 273-276.
62. Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion J, Verbist L, et al. HLA association of amoxicillin-clavulanate--induced hepatitis. Gastroenterology 1999; 117: 1181-1186.
63. Fardel O, Le Vee M. Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines. Expert Opin Drug Metab Toxicol 2009; 5: 1469-1481.
64. Trauner M, Arrese M, Lee H, Boyer JL, Karpen SJ. Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors. J Clin Invest 1998; 101: 2092-2100.
65. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK. The danger hypothesis--potential role in idiosyncratic drug reactions. Toxicology 2002; 181-182: 55-63.
66. Lu H, Choudhuri S, Ogura K, Csanaky IL, Lei X, Cheng X, et al. Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. Toxicol Sci 2008; 103: 35-45.
67. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001; 276: 35669-35675.
68. Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, Chiba K. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet 2004; 19: 453-455.
69. Furihata T, Satoh N, Ohishi T, Ugajin M, Kameyama Y, Morimoto K, et al. Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy). Pharmacogenomics J 2009; 9: 185-193.
70. Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK, et al. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. HEPATOLOGY 2006; 44: 62-74.
71. Saito S, Iida A, Sekine A, Ogawa C, Kawauchi S, Higuchi S, et al. Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J Hum Genet 2002; 47: 38-50.
72. Pauli-Magnus C, Meier PJ. Pharmacogenetics of hepatocellular transporters. Pharmacogenetics 2003; 13: 189-198.
73. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481-494.
74. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473-3478.
75. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048-1052.
76. Lang T, Haberl M, Jung D, Drescher A, Schlagenhaufer R, Keil A, et al. Genetic variability, haplotype structures, and ethnic diversity of hepatic transporters MDR3 (ABCB4) and bile salt export pump (ABCB11). Drug Metab Dispos 2006; 34: 1582-1599.
77. Pauli-Magnus C, Lang T, Meier Y, Zodan-Marin T, Jung D, Breymann C, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004; 14: 91-102.
78. Dixon PH, van Mil SW, Chambers J, Strautnieks S, Thompson RJ, Lammert F, et al. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 2009; 58: 537-544
79. Meier Y, Zodan T, Lang C, Zimmermann R, Kullak-Ublick GA, Meier PJ, et al. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J Gastroenterol 2008; 14: 38-45.
80. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132: 272-281.
81. Andrews E, Armstrong M, Tugwood J, Swan D, Glaves P, Pirmohamed M, et al. A role for the pregnane X receptor in flucloxacillin-induced liver injury. HEPATOLOGY 2010; 51: 1656-1664.
82. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 2007; 47: 566-578.
83. Bowyer Ba, Fleming CR, Ludwid J, et al. Does Lonarterm home parenteral nutrition in adult patients cause chronic liver disease? JPEN J Parenterenterl Nutr 1985; 9: 11-17.